Vous avez cherché: divalproex (Anglais - Danois)

divalproex, lamotrigine, phenytoin
divalproex, lamotrigin, phenytoin

divalproex, lamotrigine, phenytoin antidepressants
divalproex, lamotrigin, phenytoin antidepressiva

-anticonvulsants (eg divalproex, lamotrigine, phenytoin);
-antikonvulsiva (f. eks. divalproex, lamotrigin, fenytoin);

epilepsy medicines (e.g. carbamazepine, divalproex, lamotrigine, phenytoin);
lægemidler mod epilepsi (f.eks. carbamazepin, divalproex, lamotrigin, phenytoin);

phenobarbital, phenytoin, carbamazepine, divalproex, lamotrigine - medicines used to treat fits (epilepsy)
phenobarbital, phenytoin, carbamazepin, divalproex, lamotrigin anvendes til behandling af krampeanfald (epilepsi)

since no effect on the systemic clearance was observed, a clinically significant interaction would not be expected between divalproex sodium prolonged release tablets and trevicta intramuscular injection.
da der ikke blev observeret nogen effekt på den systemiske clearance, er det ikke forventeligt, at der er klinisk signifikant interaktion mellem divalproexnatrium-depottabletter og intramuskulær injektion af trevicta.

in patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3
hos patienter med maniske eller blandede episoder af manio-depressiv sygdom havde olanzapin overlegen effekt i reduktion af maniske symptomer over 3 uger i forhold til placebo og valproat.

during treatment with olanzapine in combination with lithium or divalproex, an increase of 7% from baseline body weight occurred in 17.4% of patients during acute treatment
under behandling med olanzapin i kombination med lithium eller valproat sås en øgning af legemsvægten på 7% fra baseline hos 17, 4% af patienterne i akut behandling (op til 6 uger) .

in patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks.
hos patienter med maniske eller blandede episoder af manio-depressiv sygdom havde olanzapin overlegen effekt i reduktion af maniske symptomer over 3 uger i forhold til placebo og valproat.

during treatment with olanzapine in combination with lithium or divalproex, an increase of 7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks) .
under behandling med olanzapin i kombination med lithium eller valproat sås en øgning af legemsvægten på 7% fra baseline hos 17, 4% af patienterne i akut behandling (op til 6 uger) .